Oral inhalation therapy: meeting the challenge of developing more patient-appropriate devices

References

• O’Callaghan C, Nerbrink O, Vidgen MT. The history of inhaled drug therapy. In: Drug Delivery to the Lung. Bisgaard H, O’Callaghan C, Smadlone G (Eds). Marcel Dekker, NY, USA, 1–20 (2002).
   Google Scholar
• Anderson PJ. History of aerosol therapy: liquid nebulization to MDIs to DPIs. Respir. Care50(9), 1139–1150 (2005).
   PubMedGoogle Scholar
• Thiel GC. From Suzie’s question to CFC-free: an inventor’s perspective on forty years of MDI development and regulation. In: Respiratory Drug Delivery-V. Dalby RN, Byron PR, Farr SJ (Eds). Interpharm Press, IL, USA, 115–123 (1996).
   Google Scholar
• International Standards Organization. ISO 20072 (DIS (2)). Aerosol Drug Delivery Device Design Verification: Requirements and Test Methods. ISO Geneva, Switzerland (2008).
   Google Scholar
• Becker A, Lemière C, Bérubé D et al. Summary of recommendations from the Canadian Asthma Consensus Guidelines, 2003, and Canadian Pediatric Asthma Consensus Guidelines. CMAJ173(6 Suppl.), S1–S56 (2003).
   Google Scholar
• O’Donnell DE, Aaron S, Bourbeau J et al. State of the art compendium: Canadian Thoracic Society recommendations for the management of chronic obstructive pulmonary disease. Can. Respir. J.11(Suppl. B), B7–B59 (2004).
   PubMedGoogle Scholar
• Flume PA, O’Sullivan BP, Robinson KA et al. Cystic fibrosis pulmonary guidelines: chronic medications for maintenance of lung health. Am. J. Resp. Crit. Care Med.176, 957–969 (2007).
   PubMed Web of Science ®Google Scholar
• Dolovich MB, MacIntyre NR, Andersen PJ. Consensus statement: aerosols and delivery devices. Respir. Care45(6), 589–596 (2000).
   PubMedGoogle Scholar
• Hickey AJ. Inhalation Aerosols: Physical and Biological Basis for Therapy. Informa Healthcare, NY, USA (2007).
   Google Scholar
• Bisgaard H, O’Callaghan C, Smaldone GC. Drug Delivery to the Lungs. Marcel Dekker, NY, USA (2002).
   Google Scholar
• Hess DR. Nebulizers – principles and performance. Respir. Care45(6), 609–622 (2000).
   PubMedGoogle Scholar
• Fink JB. Metered-dose inhalers, dry powder inhalers, and transitions. Respir. Care45(6), 623–635 (2000).
   PubMedGoogle Scholar
• Newman SP. Principles of metered-dose inhaler design. Respir. Care50(9), 1177–1190 (2005).
   PubMedGoogle Scholar
• Rubin BK, Fink JB. Optimizing aerosol delivery by pressurized metered-dose inhalers. Respir. Care50(9), 1191–1200 (2005).
   PubMedGoogle Scholar
• Atkins PJ. Dry powder inhalers: an overview. Respir. Care50(10), 1304–1312 (2005).
   PubMedGoogle Scholar
• Berlinski A, Waldrep JC. Four hours of continuous albuterol nebulization. Chest114(3), 847–853 (1998).
   Google Scholar
• O’Callaghan C, Wright P. The metered dose inhaler. In: Drug Delivery to the Lung. Bisgaard H, O’Callaghan C, Smaldone GC (Eds). Marcel Dekker, NY, USA, 337–370 (2002).
   Google Scholar
• Knoch M, Wunderlich E. In-vitro assessment of a new efficient nebulizer system for continuous operation. In: Respiratory Drug Delivery-IV. Byron PR, Dalby RN, Farr SJ (Eds). Interpharm Press, IL, USA, 265–271 (1994).
   Google Scholar
• Devadason SG, Everard ML, Linto JM. Comparison of drug delivery from conventional versus “venturi” nebulizers. Eur. Respir. J.10(11), 2479–2483 (1997)
   Google Scholar
• Bell JH, Hartley PS, Cox JS. Dry powder aerosols I. A new powder inhalation device. J. Pharm. Sci.60(10), 1559–1564 (1971).
   PubMed Web of Science ®Google Scholar
• Wetterlin KIL. Design and function of Turbohaler. In: A New Concept in Inhalation Therapy. Newman SP, Morén F, Crompton GK (Eds). Medicom, London, UK (1987).
   Google Scholar
• Telko MJ, Hickey AJ. Dry powder inhaler formulation. Respir. Care50(9), 1209–1227 (2005).
   PubMedGoogle Scholar
• Cougele MB, Padhi BK, Jinkurkar KA et al. Development of dry powder inhalers. Recent Pat. Drug Deliv. Formul.1, 11–21 (2007).
   Google Scholar
• Edwards DA, Hanes J, Caponetti G et al. Large porous particles for pulmonary drug delivery. Science276, 1868–1871 (1997).
   PubMed Web of Science ®Google Scholar
• Bot AL, Tarara TE, Smith DJ et al. Novel lipid based hollow porous microparticles as a platform for immunoglobulin delivery to the respiratory tract. Pharm. Res.17, 275–283 (2000).
   PubMed Web of Science ®Google Scholar
• Ostrander KD, Hovey DC, Knapp DA et al. Potential delivery of advantages of spray-dried nanocrystal colloidal budesonide with the Clickhaler. In: Respiratory Drug Delivery-VII. Dalby RN, Byron PR, Farr SJ, Peart J (Eds). Serentec Press, NC, USA, 447–449 (2000).
   Google Scholar
• Chan HK. Dry Powder aerosol delivery systems: current and future research directions. J. Aerosol Med.19(1), 21–27 (2006).
   PubMedGoogle Scholar
• Virchow JC, Crompton GK, Dal Negro R et al. Importance of inhaler devices in the management of airway disease. Respir. Med.102(1), 10–19 (2008).
   PubMed Web of Science ®Google Scholar
• Tezky T, Holquist C. Misadministration of capsules for inhalation. Drug Topics4, 48 (2005).
   Google Scholar
• Knoch M, Keller M. The customised electronic nebulizer: a new category of liquid aerosol drug delivery systems. Expert Opin. Drug Deliv.2(2), 377–390 (2005).
   PubMedGoogle Scholar
• Dhand R. Nebulizers that use a vibrating mesh or plate with multiple apertures to generate aerosol. Respir. Care47(12), 1406–1416 (2002).
   PubMedGoogle Scholar
• Newman S, Gee-Turner A. The Omron Micro-Air vibration mesh technology nebulizer, a 21st Century approach to inhalation therapy. J. Appl. Ther. Res.5, 29–33 (2005).
   Google Scholar
• Hochrainer D, Hölz H, Kreher C et al. Comparison of the aerosol velocity and spray duration of Respimat® Softmist™ inhaler and pressurized metered dose inhalers. J. Aerosol Med.18(3), 273–282 (2005).
   PubMedGoogle Scholar
• Crompton GK, Barnes PJ, Broeders M et al. The need to improve inhalation technique in Europe: a report from the Aerosol Drug Management Improvement Team. Respir. Med.100(9), 1479–1494 (2006).
   PubMed Web of Science ®Google Scholar
• Newman SP. Improving drug metering to the lung: making the patient the most important factor. In: Respiratory Drug Delivery-2006. Dalby RN, Byron PR, Peart J, Suman JD, Farr SJ (Eds). Davis Horwood International Publishing, IL, USA, 1–12 (2006).
   Google Scholar
• Leach C. Enhanced drug delivery through reformulating MDIs with HFA propellants – drug deposition and its effect on preclinical and clinical programs. In: Respiratory Drug Delivery-V. Dalby RN, Byron PR, Farr SJ (Eds). Interpharm Press Inc., IL, USA, 133–144 (1996).
   Google Scholar
• Melani AS, Zancetta D, Barbato N et al. Inhalation technique and variables associated with misuse of conventional metered-dose inhalers and newer dry powder inhalers in experienced adults. Ann. Allergy Asthma Immunol.93(5), 439–446 (2004).
   PubMed Web of Science ®Google Scholar
• Barnes P, Virchow JC, Sanchis J et al. Asthma management: important issues. Eur. Respir. Rev.14(97), 147–151 (2005).
   Google Scholar
• Corr D, Dolovich M, McCormack D et al. Design and characteristics of a portable breath actuated, particle size selective medical aerosol inhaler. J. Aerosol Sci.13(1), 1–7 (1982).
   Web of Science ®Google Scholar
• Bisgaard H, Anhøj J, Wildhaber JH. Spacer devices. In: Drug Delivery to the Lung. Bisgaard H, O’Callaghan C, Smaldone GC (Eds). Marcel Dekker, NY, USA, 389–420 (2002).
   Google Scholar
• Dolovich MB, Ahrens RC, Hess DR et al. Device selection and outcomes of aerosol therapy: evidence-based guidelines. Chest127(1), 335–371 (2005).
   PubMed Web of Science ®Google Scholar
• Mitchell JP, Nagel MW. Valved holding chambers (VHCs) for use with pressurized metered-dose inhalers (pMDIs): a review of causes of inconsistent medication delivery. Prim. Care Respir. J.16(4), 207–214 (2007).
   PubMedGoogle Scholar
• Mitchell J, Avvakoumova V, MacKay H et al. Substantial in vitro equivalence exists for anti-static and non-static versions of the same valved holding chamber (VHC) family provided pre-washing of the non-static version is undertaken to mitigate electrostatic charge. In: Drug Delivery to the Lungs-19. The Aerosol Society, Edinburgh, UK (2008).
   Google Scholar
• Dolovich MB. In my opinion – interview with the expert. Pediatric Asthma, Allerg. Immunol.17, 292–300 (2004).
   Google Scholar
• Canadian Medical Association. Canadian asthma consensus report, 1999. CMAJ161(11 Suppl.), S1–S62 (1999).
   PubMed Web of Science ®Google Scholar
• Morton RW, Mitchell JP. Design of facemasks for delivery of aerosol-based medication via pressurized metered dose inhaler with valved holding chamber: key issues that affect performance. J. Aerosol Med.20(S1), S29–S45 (2007).
   Google Scholar
• Nagel MW, Avvakoumova V, MacKay H et al. Medication delivery via infant and child valved holding chambers (VHCs) with facemask is aided with inhalation flow indicator. Eur. Respir. J.32(S52), S3497 (2008).
   Google Scholar
• Velsor-Friedrich B, Vlasses F, Moberly J et al. Talking with teems about asthma management. J. School Nursing20(3), 140–148 (2004).
   PubMedGoogle Scholar
• Everard ML. Inhaler devices in infants and children: challenges and solutions. J. Aerosol Med.17(2), 186–195 (2004).
   PubMedGoogle Scholar
• Purewal TS. Formulation of metered dose inhalers. In: Metered Dose Inhaler Technology. Purewal TS, Grant DJW (Eds),.Interpharm Press, IL, USA, 9–65 (1998).
   Google Scholar
• Holt S, Holt A, Weatherall M et al. Metered dose inhalers: a need for dose counters. Respirology10, 105–106 (2005).
   PubMed Web of Science ®Google Scholar
• Ogren RA, Baldwin JL, Simon RA. How patients determine when to replace their metered-dose inhalers. Ann. Allergy Asthma Immunol.75, 485–489 (1995).
   PubMedGoogle Scholar
• Fink JB, Rubin BK. Problems with inhaler use: a call for improved clinician and patient education. Respir. Care50(10), 1360–1375 (2005).
   PubMedGoogle Scholar
• Sander N, Fusco-Walker SJ, Harder JM et al. Dose counting and the use of pressurized metered-dose inhalers: running on empty. Ann. Allergy Asthma Immunol.97(1), 34–38 (2006).
   PubMed Web of Science ®Google Scholar
• Purkins G. Retrofitting of dose counters to pMDIs. In: Respiratory Drug Delivery Europe – 2007. Dalby RN, Byron PR, Peart J, Suman JD (Eds). Davis International Healthcare Publishing, IL, USA, 221–224 (2007).
   Google Scholar
• Scarrott P. An application of quality by design (QBD) and process analytical technology (PAT) to the development of force-driven dose counters for pressurized metered dose inhalers. In: Drug Delivery to the Lungs-19. The Aerosol Society, Edinburgh, UK, Part A, 10–13 (2008).
   Google Scholar
• Rau JL. Practical problems with aerosol therapy in COPD. Respir. Care51(2), 158–172 (2006).
   PubMed Web of Science ®Google Scholar
• Richter K. Successful use of systems in asthmatic patients: key parameters. Respir. Med.98, S22–S27 (2004).
   PubMed Web of Science ®Google Scholar
• DeGroot JS, Gray S, Wang M et al. Exubera insulin pulmonary inhaler: a comparison of aerosol performance following simulated long-term use and real-time patient use. In: Respiratory Drug Delivery-2006. Byron PR, Dalby RN, Peart J, Suman JD, Farr SJ (Eds). Davis International Healthcare Publishing, IL, USA, 713–716 (2006).
   Google Scholar
• Japsen B. Inhaled insulin’s cost may take breath away. Chicago Tribune, 2nd February (2006).
   Google Scholar
• Berenson A. Pfizer Drug for diabetes is lagging. NY Times, 10 April (2007).
   Google Scholar
• Mitchell JP, Nagel MW, Bates SL, Doyle CC. In-vitro performance of a breath-actuated nebulizer for the delivery of methacholine chloride. Respir. Care, 48(1), 46–51 (2003).
   Google Scholar
• Denyer J, Nikander K. Halolite™: a novel liquid drug aerosol system. In: Respiratory Drug Delivery-VI. Dalby RN, Byron PR, Farr SJ (Eds). Interpharm Press, IL, USA, 311–314 (1996).
   Google Scholar
• Denyer J, Nikander K, Smith NJ. Adaptive aerosol delivery (AAD) technology. Expert Opin. Drug Deliv.1(1), 165–176 (2004).
   PubMedGoogle Scholar
• Scheuch G, Brand P, Müllinger T et al. Regional drug targeting within the lungs by controlled inhalation with the AKITA system. In: Respiratory Drug Delivery-VIII. Dalby RN, Byron PR, Peart J, Farr SJ (Eds). Davis Horwood Int. Publishing, NC, USA, 471–473 (2002).
   Google Scholar
• Borgshulte M, Germer M, Hug M et al. Means to optimize drug delivery from a novel electronic inhaler. In: Respiratory Drug Delivery-IX. Dalby RN, Byron PR, Peart J, Suman JD, Farr SJ (Eds). Davis Horwood Int. Publishing, IL, USA, 605–608 (2004).
   Google Scholar
• Schuster J, Rubsamen R, Lloyd P et al. The AERx™ aerosol delivery system. Pharm. Res.14, 354–357 (1997).
   PubMed Web of Science ®Google Scholar
• Luyt C-E, Clavel M, Guntupalli K et al. NKTR-061(inhaled amikacin) BID achieves high epithelial lining fluid concentrations in pneumonic portions of lung. Poster 516. Presented at: American Thoracic Society International Conference. Toronto, Ontario, Canada, 16– 21 May, 2008.
   Google Scholar
• Thiphawong J, Otulana B, Clauson P et al. Pulmonary insulin administration using the AERx® insulin diabetes system. Diabetes Technol. Therapeut.4, 499–504 (2002).
   Google Scholar
• Keller M, Bitterle E, Tservistas M et al. Cyclosporine A: investigation on formulation independent toxicity in a calu-3 cell culture model and characterization of aerosols generated by the eFLOW® electronic nebulizer. In: Respiratory Drug Delivery-2006. Dalby RN, Byron PR, Peart J, Suman JD, Farr SJ (Eds). Davis Horwood Int. Publishing, IL, USA, 605–608 (2006).
   Google Scholar
• Tronde A, Baran G, Eirefelt S et al. Miniaturized nebulization catheters: a new approach for delivery of defined aerosol doses to the rat lung. J. Aerosol Med.15(3), 283–286 (2002).
   PubMedGoogle Scholar
• Finlay JB, Mitchell JP, Baran G et al. Delivery of medication as large particles at the carina of an in vitro lung model is effective using a nebulizing catheter. In: Drug Delivery to the Lungs-16. The Aerosol Society, London, UK, 34–37 (2005).
   Google Scholar
• Nambiar MP, Wright BS, Rezk PE et al. Development of a microinstillation model of inhalation exposure to assess lung injury following exposure to toxic chemicals and nerve agents in guinea pigs. Toxicol. Mechanisms Methods16, 295–306 (2006).
   PubMed Web of Science ®Google Scholar
• Selting K, Waldrep JC, Reinero C et al. Feasibility and safety of targeted cisplatin delivery to a select lung lobe in dogs via the AeroProbe® intracorporeal nebulizing catheter. J. Aerosol Med. Pulm. Drug Deliv.21(3), 255–268 (2008).
   Google Scholar
• Köping-Höggård M, Issa M M, Köhler T et al. A miniaturized nebulization catheter for improved gene delivery to the mouse lung. J. Gene Med.7(9), 1215–1222 (2005).
   PubMed Web of Science ®Google Scholar
• Koehler DR, Frndova H, Leung K et al. Aerosol delivery of an enhanced helper-dependent adenovirus formulation to rabbit lung using an intratracheal catheter. J. Gene Med.7(11), 1409–1420 (2005).
   PubMed Web of Science ®Google Scholar
• Islam N, Gladki E. Dry powder inhalers (DPIs): a review of device reliability and innovation. Int. J. Pharm.360, 1–11 (2008).
   PubMed Web of Science ®Google Scholar
• Clark A. Pulmonary delivery technology: recent advances and potential for the new millennium. In: Pharmaceutical Inhalation Aerosol Technology. AJ Hickey (Ed.). Marcel Dekker, NY, USA, 571–592 (2004).
   Google Scholar
• Keller M, Gallem T, Stangl R et al. Requirements on formulations and nebulizer design: features to improve pulmonary drug delivery in pre-school children, toddlers and infants. In: Drug Delivery to the Lungs-17. The Aerosol Society, Edinburgh, UK, 10–13 (2006).
   Google Scholar
• Richardson PC, Boss AH. Technosphere® insulin technology. Diabetes Technol. Therapeut.9, S65–S72 (2007).
   PubMed Web of Science ®Google Scholar
• Patton JS, Byron PR. Inhaling medicines: delivering drugs to the body through the lungs. Nature Rev. Drug Discovery6(1), 67–74 (2007).
   PubMed Web of Science ®Google Scholar
• Rand CS. Patient adherence with COPD therapy. Eur. Respir. Rev.14(96), 97–101 (2005).
   Google Scholar
• Everard ML. Trying to deliver aerosols to upset children is a thankless task. Arch. Dis. Child.82, 428 (1995).
   Google Scholar
• Everard ML. Role of inhaler competence and contrivance in ‘difficult asthma’. Paediatr. Respir. Rev.4(2), 135–142 (2003).
   PubMedGoogle Scholar
• Postma DS, Sevette C, Martinat Y et al. Treatment of asthma by the inhaled corticosteroid ciclesonide given either in the morning or evening. Eur. Respir. J.17(6), 1083–1088 (2001).
   PubMed Web of Science ®Google Scholar
• Mansfield LE. The future of the long-acting β-adrenergic bronchodilators in the treatment of asthma. Allergy Asthma Proc.29(2), 103–108 (2008).
   Google Scholar
• Sachs A. Knocking down disease: new uses of RNAi might transform all of its possibilities into realities. Drug Discovery and Development,33–35 (2008).
   Google Scholar
• Gabizon AA. Pegylated liposomal doxorubicin: metamorphosis of an old drug into a new form of chemotherapy. Cancer Invest.19(4), 424–436 (2001).
   PubMed Web of Science ®Google Scholar
• Torchilin VP, Lukyanov AN. Peptide and protein drug delivery to and into tumors: challenges and solutions. Drug Discovery Today8, 259–266 (2003).
   PubMed Web of Science ®Google Scholar
• Möschwitzer J, Müller RH. Drug nanocrystals: the universal formulation approach for poorly soluble drugs. In: Nanoparticulate Drug Delivery Systems. Thassu D, Deleers M, Pathak Y (Eds). Informa Healthcare USA Inc., NY, USA, 71–88 (2007).
   Google Scholar
• Chan C, Valle-Leutri F, Clark J. Self-titrated aerosolized liposome-encapsulated fentanyl results in rapid onset and sustained analgesia following ACL knee surgery. Anesthesiology101, A77 (2004).
   Google Scholar